THERAPY DOSSIER · th-8cbd669ca897

Recombinant vascular endothelial growth factor (VEGF)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04075136 ↗PHASE4withdrawn

OCTA-Directed PDT Triple Therapy Versus Standard Anti-VEGF Monotherapy in Exudative AMD

Exudative Age Related Macular Degeneration

Enrolment: 0 · Results not recorded

NCT00917384 ↗PHASE3completed

Phase 3 Study of IMC-1121B (Ramucirumab) and BSC Versus Placebo and BSC in Metastatic Gastric/GEJ Adenocarcinoma

Gastric Cancer · Adenocarcinoma

Enrolment: 355 · Results not recorded

NCT01832259 ↗PHASE2completed

Neoadjuvant Phase II Study of VEGF TKI (Pazopanib) in High-Risk Prostate Cancer

Adenocarcinoma of the Prostate

Enrolment: 30 · Results not recorded

NCT06116890 ↗PHASE2active not recruiting

Phase 2 Study of KHK4951, a VEGFR Inhibitor, in Neovascular AMD

Neovascular Age-Related Macular Degeneration (nAMD)

Enrolment: 180 · Results not recorded

NCT03390062 ↗PHASE2unknown

Apatinib for Treatment of Recurrent High-grade Glioma

Glioma

Enrolment: 30 · Results not recorded

NCT00749021 ↗PHASE1completed

Ranibizumab (Anti-VEGF Fragment) for Subfoveal Pigment Epithelial Detachment With Choroidal Neovascularization

Retinal Pigment Epithelial Detachment

Enrolment: 40 · Results not recorded

NCT00844987 ↗Phase not recordedcompleted

Importance of VEGF, HGF and PDGF as New Indicators of Myocardial Ischemic Injury

Acute Coronary Syndrome

Enrolment: 120 · Results not recorded

NCT02603315 ↗Phase not recordedcompleted

Correlation Between Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results

Malignant Pleural Mesotheliomas

Enrolment: 50 · Results not recorded

NCT01871207 ↗Phase not recordedcompleted

Serum and Intraocular Levels of Erythropoietin and VEGF in Type 2 Diabetes With Proliferative Retinopathy

Diabetic Retinopathy

Enrolment: 53 · Results not recorded

NCT03897192 ↗Phase not recordedcompleted

Long-term Outcome of PIC/MFC With Active CNV Managed With Anti-VEGF

Punctate Inner Choroidopathy

Enrolment: 14 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29446207 ↗2018Reported benefit

VEGF mitigates histone-induced pyroptosis in the remote liver injury associated with renal allograft ischemia-reperfusion injury in rats.

RatIschaemia-reperfusionRenalBrown-Norway donors, Lewis recipientsMalen = n = 6 per group in vivo; n = 8 in vitroIntravenousVEGF 10 mg/kg; comparator agents histone H3 10 or 50 mg/kg,…Given in association with transplantation; liver and blood harvested 24 h after…

Model: Brown-Norway to Lewis orthotopic renal allograft transplantation with 24 h cold ischaemia, causing remote liver injury

VEGF reduced hepatic caspase-1 and ASC expression, TUNEL positive cells, liver injury score, macrophage infiltration, IL-1 beta and IL-18, and lowered ALT and AST.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…